Literature DB >> 1966669

The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells.

N A Marsh1, A J Minter, C N Chesterman.   

Abstract

Human umbilical vein endothelial cells (HUVEC) were cultured in the presence of various glycosaminoglycans and the intracellular levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) measured by ELISA. 10 IU/ml heparin (90 micrograms/ml) brought about a significant (20-fold) increase in intracellular tPA levels over the 6-day culture period; intracellular PAI-1 levels were significantly decreased (by 60-70%) and culture growth rate promoted. The final cell density of heparin-containing cultures was 1.7 to 2.3 times greater than that of control cultures. Low molecular weight heparin (First International Standard) had similar effects but was less potent than unfractionated heparin. Chondroitin sulphate and heparan sulphate had no effect on tPA and PAI-1 levels but dermatan sulphate reduced PAI-1 significantly. The changes observed following exposure of HUVEC to heparin are consonant with the view that glycosaminoglycans may affect endothelial production of fibrinolytic components.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1966669

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery.

Authors:  Barry Dixon; Duncan J Campbell; John D Santamaria
Journal:  Intensive Care Med       Date:  2008-02-27       Impact factor: 17.440

2.  Gene expression of fibrinolytic markers in coronary thrombi.

Authors:  Jostein Nordeng; Svein Solheim; Sissel Åkra; Hossein Schandiz; Pavel Hoffmann; Borghild Roald; Bjørn Bendz; Harald Arnesen; Ragnhild Helseth; Ingebjørg Seljeflot
Journal:  Thromb J       Date:  2022-04-29

3.  A phase 1 trial of nebulised heparin in acute lung injury.

Authors:  Barry Dixon; John D Santamaria; Duncan J Campbell
Journal:  Crit Care       Date:  2008-05-06       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.